Nephrology and Infectious Diseases Research and Development Group, INEB-(I3S), University of Porto, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal.
Exp Biol Med (Maywood). 2014 Apr;239(4):502-8. doi: 10.1177/1535370214522182. Epub 2014 Mar 5.
Renalase is a recently described enzyme secreted by the kidney into both plasma and urine, where it was suggested to degrade catecholamines contributing to blood pressure control. While there is a controversy regarding the relationship between renal function and plasma renalase levels, there is virtually no data in humans on plasma renalase activity as well as on both urine renalase levels and activity. We prospectively examined the time course of plasma and urine renalase levels and activity in 26 end-stage renal disease (ESRD) patients receiving a cadaver kidney transplant (cadaver kidney recipients [CKR]) before surgery and during the recovery of renal function up to day 90 post transplant. The relationship with sympathetic and renal dopaminergic activities was also evaluated. The recovery of renal function in CKR closely predicted decreases in plasma renalase levels (r = 0.88; P < 0.0001), urine renalase levels (r = 0.75; P < 0.0001) and urine renalase activity (r = 0.56; P < 0.03), but did not predict changes in plasma renalase activity (r = -0.02; NS). Plasma norepinephrine levels positively correlated with plasma renalase levels (r = 0.64, P < 0.002) as well as with urine renalase levels and activity (r = 0.47 P < 0.02; r = 0.71, P < 0.0005, respectively) and negatively correlated with plasma renalase activity (r = -0.57, P < 0.002). By contrast, plasma epinephrine levels positively correlated with plasma renalase activity (r = 0.67, P < 0.0001) and negatively correlated with plasma renalase levels (r = -0.62, P < 0.003). A significant negative relationship was observed between urine dopamine output and urine renalase levels (r = -0.48; P < 0.03) but not with urine renalase activity (r = -0.33, NS). We conclude that plasma and urine renalase levels closely depend on renal function and sympathetic nervous system activity. It is suggested that epinephrine-mediated activation of circulating renalase may occur in renal transplant recipients with good recovery of renal function. The increase in plasma renalase activity observed in ESRD patients and renal transplant recipients can be explained on the basis of reduced inhibition of the circulating enzyme.
肾酶是一种最近被描述的由肾脏分泌到血浆和尿液中的酶,它被认为可以降解儿茶酚胺,从而有助于控制血压。虽然肾功能与血浆肾酶水平之间存在争议,但实际上人类关于血浆肾酶活性以及尿肾酶水平和活性的数据几乎没有。我们前瞻性地研究了 26 名接受尸体肾移植(尸体肾受体[CKR])的终末期肾病(ESRD)患者手术前和肾功能恢复至移植后 90 天期间的血浆和尿液肾酶水平和活性的时间过程。还评估了与交感神经和肾脏多巴胺能活性的关系。CKR 肾功能的恢复与血浆肾酶水平的降低密切相关(r = 0.88;P <0.0001)、尿肾酶水平(r = 0.75;P <0.0001)和尿肾酶活性(r = 0.56;P <0.03),但不预测血浆肾酶活性的变化(r = -0.02;NS)。血浆去甲肾上腺素水平与血浆肾酶水平(r = 0.64,P <0.002)以及尿肾酶水平和活性(r = 0.47,P <0.02;r = 0.71,P <0.0005)呈正相关,与血浆肾酶活性(r = -0.57,P <0.002)呈负相关。相比之下,血浆肾上腺素水平与血浆肾酶活性呈正相关(r = 0.67,P <0.0001),与血浆肾酶水平呈负相关(r = -0.62,P <0.003)。尿多巴胺输出与尿肾酶水平呈显著负相关(r = -0.48;P <0.03),但与尿肾酶活性无关(r = -0.33,NS)。我们的结论是,血浆和尿肾酶水平与肾功能和交感神经系统活动密切相关。提示在肾功能恢复良好的肾移植受者中,可能会发生肾上腺素介导的循环肾酶的激活。在 ESRD 患者和肾移植受者中观察到的血浆肾酶活性增加可以基于循环酶抑制作用的降低来解释。